Sugi Predict

Sugi Predict / Compounds / SCHEMBL659052

SCHEMBL659052

SCHEMBL659052

COc1ccc(CCCC(N)=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 2/20 0.68
▸ F2RL1 P55085 1/20 0.61
▸ CALM1 P0DP23 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.57
▸ POLB P06746 1/20 0.57
▸ RECQL P46063 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ TAAR1 Q96RJ0 1/20 0.55
▸ PLAAT3 P53816 1/20 0.55
▸ PLAAT5 Q96KN8 1/20 0.55
▸ PLAAT2 Q9NWW9 1/20 0.55
▸ PLAAT4 Q9UL19 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20019549 0.95 ALOX5 (0.61) ALOX5F2RL1CALM1POLBTAAR1
SCHEMBL13522667 0.93 ALOX5 (0.59) ALOX5F2RL1CALM1POLBTAAR1
SCHEMBL933946 0.93 ALOX5 (0.59) ALOX5F2RL1CALM1POLBTAAR1
SCHEMBL1413843 0.91 F2RL1 (0.68) ALOX5F2RL1ALDH1A1POLBL3MBTL1
SCHEMBL11904891 0.86 F2RL1 (0.62) ALOX5F2RL1ALDH1A1POLBKMT2A
SCHEMBL2169720 0.86 F2RL1 (0.62) ALOX5F2RL1ALDH1A1POLBKMT2A
SCHEMBL503646 0.85 ALOX5 (0.68) ALOX5F2RL1CALM1ALDH1A1KMT2A
SCHEMBL1105476 0.85 ALOX5 (0.68) ALOX5F2RL1CALM1ALDH1A1POLB
SCHEMBL8843136 0.85 CNR1 (0.60) ALOX5F2RL1CALM1KMT2A
SCHEMBL6710455 0.84 ALOX5 (0.66) ALOX5F2RL1CALM1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4739625-B2 — — 2011-08-03 — — JP claimed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO claimed
US-20040142981-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-07-22 — — US claimed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 — — US claimed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 — — WO claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 — — WO claimed
EP-1206467-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2002-05-22 — — EP claimed
WO-2001014371-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2001-03-01 — — WO claimed
WO-2025082283-A1 LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE 四川科伦博泰生物医药股份有限公司 2025-04-24 — — WO disclosed
WO-2025041809-A1 METHOD FOR PRODUCING DEUTERATED COMPOUND 国立大学法人九州大学 2025-02-27 — — WO disclosed
WO-1995028418-A2 TACHYKININ ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1995-10-26 — — WO disclosed
US-4971990-A HYPOTENSIVE AGENTS, DYSUREA HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1990-11-20 — — US disclosed
US-4600777-A Method of preparing 1-alkyl-7-oxodecahydroquinolines, and cis(±) and tran(±)isomers so prepared ELI LILLY AND COMPANY (US) 1986-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 ALOX5 2283/4885F2RL1 3834/4885CALM1 2258/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 ALOX5 2283/4885F2RL1 3834/4885CALM1 2258/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 ALOX5 2283/4885F2RL1 3834/4885CALM1 2258/4885
US-20040142981-A1 Antibacterial benzoic acid derivatives GABRD, PHB1, GABBR1 ALOX5 498/4885F2RL1 3096/4885CALM1 4143/4885
US-20040110802-A1 Antibacterial benzoic acid derivatives GABRD, GABBR1, GABRA1 ALOX5 413/4885F2RL1 2957/4885CALM1 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.